THE IBN SINA PHARMACEUTICAL INDUSTRY PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 251.8 BDT | +0.48% |
|
-0.87% | -12.14% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 11.22B 96.69M 131M | Sales 2025 * | 12.74B 110M 149M | Capitalization | 7.87B 67.78M 92.12M |
|---|---|---|---|---|---|
| Net income 2024 * | 712M 6.13M 8.34M | Net income 2025 * | 813M 7M 9.52M | EV / Sales 2024 * | 0.7 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.62 x |
| P/E ratio 2024 * |
11
x | P/E ratio 2025 * |
9.68
x | Employees | 4,000 |
| Yield 2024 * |
2.82% | Yield 2025 * |
3.22% | Free-Float | 47.44% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.48% | ||
| 1 week | -0.87% | ||
| Current month | -1.87% | ||
| 1 month | -3.23% | ||
| 3 months | -8.50% | ||
| 6 months | -12.14% | ||
| Current year | -12.14% |
1 week
248.00
258.00
1 month
248.00264.00
Current year
248.00286.60
1 year
248.00289.70
3 years
240.50348.00
5 years
192.00348.00
10 years
61.32348.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 69 | 02-12-31 | |
Chowdhury Hasan
DFI | Director of Finance/CFO | 70 | 12-12-31 |
Mohammad Uddin
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 76 | 82-12-31 | |
Abdus Bhuiyan
BRD | Director/Board Member | 65 | 22-01-15 |
| Chief Executive Officer | 69 | 02-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 251.8 | +0.48% | 3,271 |
| 24-05-12 | 250.6 | -0.83% | 8,640 |
| 24-05-09 | 252.7 | -0.32% | 6,292 |
| 24-05-08 | 253.5 | -0.39% | 6,905 |
| 24-05-07 | 254.5 | +0.20% | 11,118 |
End-of-day quote Dhaka S.E., May 12, 2024
More quotes
The IBN SINA Pharmaceutical Industry Ltd is a pharmaceutical company in Bangladesh. The Company is engaged in the production of pharmaceutical drugs and natural medicines. It sells its products to both local and international market. The Company offers its products in a range of therapeutic areas, such as anti-allergic occular, anti-arthritis supplement, anti-asthmatic, anti-emetic, antifungal, anti-glucoma, anti-histamine, anti-malarial, anti-protozoal, antibiotic, antivertigo agent, antiviral, cough expectorant, dry eye syndrome, hormone products, nasal decongestant, topical, urinary incontinence and sterois-occular. The Company offers its products under various brand names, such as Aceril, Acipam, Algirex, Azopt, Antigrain, Bactin, Betasil, Buscon, Bromofen, Camide, Cardil, Cloram-D, Cinarzin, Dermacort, Dexon, Donadin, Emiston, Eylon, Fexomin, Fungin, Fruson, Gatsina, Glamor, Hexyclore, Iluca, Inseac, Ketof, Lansina, Lytex, Malex, Metsina, Natazol and Neuralgin.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
251.8
BDT
Average target price
390
BDT
Spread / Average Target
+54.88%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.14% | 67.03M | |
| +21.09% | 43.27B | |
| +25.39% | 22.92B | |
| +19.22% | 15.43B | |
| +13.51% | 12.95B | |
| +44.01% | 11.83B | |
| -6.70% | 6.91B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.26% | 5.55B |
- Stock Market
- Equities
- IBNSINA Stock